

**M.O. 2020 089**

**Order of the Minister of Health and Social Services**

An Act respecting prescription drug insurance  
(chapter A-29.01)

CONCERNING the Regulation to amend the Regulation respecting the List of medications covered by the basic prescription drug insurance plan

HAVING REGARD TO section 60 of the Act respecting prescription drug insurance (chapter A-29.01) which stipulates that the Minister of Health and Social Services shall draw up by regulation a list of the medications the cost of which is covered by the basic prescription drug insurance plan;

HAVING REGARD TO the Regulation respecting the List of medications covered by the basic prescription drug insurance plan (CQLR, chapter A-29.01, r. 3);

HAVING REGARD TO order 2020-083 dated 28 October 2020, making the Regulation to amend the Regulation respecting the List of medications covered by the basic prescription drug insurance plan, which replaces SCHEDULE 1 to the Regulation respecting the List of medications covered by the basic prescription drug insurance plan;

CONSIDERING that it is necessary to amend this Schedule;

CONSEQUENTLY, the Minister of Health and Social Services makes the Regulation to amend the Regulation respecting the List of medications covered by the basic prescription drug insurance plan, the text of which is attached hereto.

Québec, 13 November 2020

Original signed by

CHRISTIAN DUBÉ  
Minister of Health and Social Services

# REGULATION TO AMEND THE REGULATION RESPECTING THE LIST OF MEDICATIONS COVERED BY THE BASIC PRESCRIPTION DRUG INSURANCE PLAN

An Act respecting prescription drug insurance  
(chapter A-29.01, s. 60)

1. The Regulation respecting the List of medications covered by the basic prescription drug insurance plan (chapter A-29.01, r. 3) is amended, in SCHEDULE 1:

(1) by deleting, in Appendix IV, the entries entitled “OSELTAMIVIR PHOSPHATE” and “ZANAMIVIR”;

(2) by inserting, in the listing of the therapeutic subclasses under class 8:00 entitled “ANTI-INFECTIVE AGENTS” and after therapeutic subclass 8:18.20 entitled “interferons”, the following :

“8:18.28 neuraminidase inhibitors”;

(3) by inserting, after the boxed texts of therapeutic subclass 8:18.20 entitled “INTERFERONS”, the following:

## “ 8:18.28 NEURAMINIDASE INHIBITORS

### OSELTAMIVIR PHOSPHATE

Caps.

30 mg **PPB**

02497409	<i>Jamp Osetamivir</i>	Jamp	10	10.49	➔	1.0485
02497352	<i>Mar-Osetamivir</i>	Marcan	10	10.49	➔	1.0485
02497441	<i>Mint-Osetamivir</i>	Mint	10	10.49	➔	1.0485
02472635	<i>NAT-Osetamivir</i>	Natco	10	10.49	➔	1.0485
02304848	<i>Tamiflu</i>	Roche	10	19.50		1.9500

Caps.

45 mg **PPB**

02497360	<i>Mar-Osetamivir</i>	Marcan	10	23.91	➔	2.3910
02472643	<i>NAT-Osetamivir</i>	Natco	10	23.91	➔	2.3910
02304856	<i>Tamiflu</i>	Roche	10	30.00		3.0000

Caps.

75 mg **PPB**

02497425	<i>Jamp Osetamivir</i>	Jamp	10	20.79	➔	2.0785
02497379	<i>Mar-Osetamivir</i>	Marcan	10	20.79	➔	2.0785
02497476	<i>Mint-Osetamivir</i>	Mint	10	20.79	➔	2.0785
02457989	<i>NAT-Osetamivir</i>	Natco	10	20.79	➔	2.0785
02241472	<i>Tamiflu</i>	Roche	10	39.00		3.9000

Oral Susp.

6 mg/mL **PPB**

02499894	<i>NAT-Osetamivir</i>	Natco	65 ml	18.27	➔	0.2811
02381842	<i>Tamiflu</i>	Roche	65 ml	19.50		0.3000

### ZANAMIVIR

Inh. Pd. (App.)

5 mg/coque (4)

02240863	<i>Relenza</i>	GSK	5	36.54		
----------	----------------	-----	---	-------	--	--

(4) by deleting, in the section “EXCEPTIONAL MEDICATIONS” the boxed texts entitled “OSELTAMIVIR PHOSPHATE” and “ZANAMIVIR”.

2. This Regulation comes into force on the date of its publication on the website of the Régie de l’assurance maladie du Québec.